Comparing healing effects of growth factor-rich plasma and autologous serum in aniridia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the healing properties of growth factor-rich plasma versus autologous serum in patients with aniridia, a condition that leads to corneal scarring and clouding. Blood samples will be collected from both aniridia patients and healthy controls, with half used to create autologous serum and the other half for growth factor-rich plasma. The study aims to evaluate the in vitro healing and anti-fibrotic effects of these treatments by analyzing conjunctival impressions. The goal is to determine which treatment may better promote epithelial healing and reduce fibrosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For patients with aniridia:

* With aniridia
* Patient weighing more than 43 kg
* If the patient is being treated with autologous serum, a delay of 8 weeks after the last blood collection
* If a blood donation has been made, a delay of 8 weeks must be respected after the last donation

For controls:

* Non-aniridia (no clinical signs)
* Weighing more than 43 kg
* Matched to a case for sex and age +/-10 years
* No known diabetes
* If a blood donation has been made, a delay of 8 weeks must be respected after the latter

Exclusion Criteria:

* Insufficient sample volume
* No conjunctival print
* HBV, HCV, HIV serology positive
* Aniridia not genetically confirmed for cases For each patient excluded, a new patient will be included in order to maintain the number of patients required for data analysis.

Where it's running

• Hôpital Fondation A. de Rothschild
  Paris, France Recruiting

Study contacts

• Principal investigator: Damien GUINDOLET — Hôpital Fondation A. de Rothschild
• Study coordinator: Amélie YAVCHITZ
• Email: ayavchitz@for.paris
• Phone: (0)1 48 03 64 54

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Expansion of a genetic and data repository for rare eye diseases

  This study is collecting genetic and health information from people with rare eye diseases like Aniridia and Best disease, along with their family members, to help improve understanding and treatment options for these conditions.

  Recruiting at 2 sites National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 1 other locations · NCT06491615

• National cohort for congenital eye defects

  This study looks at how congenital eye defects affect vision and development in newborns, children, and adults over ten years to help improve care for those with these conditions.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris, Île-de-France Region · NCT05954403

• Registry for patients with rare diseases

  This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.

  Recruiting Sanford Health · Sioux Falls, South Dakota · NCT01793168

• Survey on patient knowledge and manifestations of congenital aniridia

  This study is trying to see how much people with congenital aniridia and their families know about the condition and what symptoms they experience.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT05390801

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.